Media stories about SciClone Pharmaceuticals (NASDAQ:SCLN) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. SciClone Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.2462590692436 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- SciClone Announces End Of Go-Shop Period With No Parties Designated As Excluded Parties (finance.yahoo.com)
- SciClone Pharmaceuticals, Inc. (SCLN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS (americanbankingnews.com)
- SciClone Reports Second Quarter 2017 Financial Results (finance.yahoo.com)
- SciClone posts 2Q profit (finance.yahoo.com)
Shares of SciClone Pharmaceuticals (NASDAQ SCLN) opened at 11.05 on Friday. The stock has a market cap of $576.71 million, a PE ratio of 13.63 and a beta of 1.71. SciClone Pharmaceuticals has a 12-month low of $8.55 and a 12-month high of $11.43. The firm has a 50 day moving average price of $10.97 and a 200 day moving average price of $10.15.
SciClone Pharmaceuticals (NASDAQ:SCLN) last announced its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.02. SciClone Pharmaceuticals had a return on equity of 21.10% and a net margin of 25.18%. The business had revenue of $44.52 million for the quarter. On average, equities analysts expect that SciClone Pharmaceuticals will post $0.94 EPS for the current year.
Separately, Maxim Group set a $14.00 price target on SciClone Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, May 11th.
In related news, CFO Wilson Wai-Shun Cheung sold 40,500 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $10.75, for a total value of $435,375.00. Following the sale, the chief financial officer now directly owns 14,372 shares in the company, valued at $154,499. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Friedhelm Blobel sold 21,464 shares of the business’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $9.32, for a total value of $200,044.48. Following the completion of the sale, the chief executive officer now owns 107,692 shares in the company, valued at $1,003,689.44. The disclosure for this sale can be found here. Insiders sold 235,500 shares of company stock worth $2,479,764 over the last 90 days. Company insiders own 5.16% of the company’s stock.
SciClone Pharmaceuticals Company Profile
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
What are top analysts saying about SciClone Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for SciClone Pharmaceuticals Inc. and related companies.